The i-SIGHT2 pivotal clinical trial is evaluating the investigational i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration (AMD), and on July 1, 2026, Texas Retina’s Patrick D. Williams, MD, was the first in the US to randomize a patient for this study. He serves as Texas Retina’s Director of Clinical Research for Fort Worth.
The i-SIGHT2 trial is a randomized, sham-controlled study designed to evaluate the safety and effectiveness of the i-Lumen AMD System, a noninvasive, office-based bioelectric therapy intended to improve retinal electrophysiology and visual function in patients with vision loss caused by intermediate to advanced dry AMD.
Texas Retina also participated in the i-SIGHT feasibility study that was completed last year and found that 55% of patients receiving treatment achieved a significant improvement in vision. Positive changes in retinal electrophysiology and structural biomarkers associated with photoreceptor health were also demonstrated. The current clinical trial builds on the results of that study.
Understanding Dry AMD
The most common form of AMD, dry AMD affects the macula, the central part of the retina responsible for sharp, detailed vision. The light-sensitive cells in the macula gradually break down, and small yellow deposits called drusen can build up under the retina. As a result, central vision slowly becomes blurry or distorted.
“Treating dry AMD remains a significant challenge,” says Dr. Williams. “It is driven by gradual, complex degeneration of the retina and retinal pigment epithelium. We continue to seek meaningful new therapies to prevent or slow the progressive central vision loss before irreversible retinal damage occurs. Our goal is to help patients preserve critical visual functions such as reading, driving and facial recognition, so that they can maintain their independence.”
About the i-Lumen AMD System
The investigational therapy in the iSIGHT2 trial delivers low-level microcurrent stimulation through the eyelid to increase the transepithelial potential and repolarize retinal pigment epithelium (RPE) cells. This approach is intended to improve photoreceptor cell function by restoring retinal electrophysiologic signaling.
For more information or to determine eligibility for the iSIGHT2 trial, click HERE to contact study coordinator Brandi Richardson or call her at (214) 692-6885, ext. 1.
Physicians can click HERE to refer a patient for consideration.
Click HERE to access a full listing of clinical trials currently enrolling at Texas Retina.